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 In the United States, the estimated lifetime risk of developing knee osteoarthritis is 
approximately 44%. Therefore, animal models are necessary to study the etiology of the 
disease as well as the efficacy of therapeutic treatments. In this study, a combination of 
anterior cruciate ligament transection (ACLT) and partial medial meniscal transection 
(pMMT) was performed on rat knees to investigate changes in behavior, cartilage, and 
bone morphology due to post-traumatic osteoarthritis (PTOA). Hyaluronic acid (HA) intra-
articular injection was administered to the knee one week after the surgeries. ACLT + 
 xi 
pMMT surgery resulted in a temporary contralateral preference in static weight bearing, 
minor degeneration of the articular cartilage, and generally decreased bone quality. 
However, among the parameters analyzed, the most sensitive parameter for characterizing 
PTOA changes in the ACLT + pMMT model was trabecular thickness from µCT analyses. 
Treatment with HA was also found to attenuate the progression of PTOA changes in 
articular cartilage and bone morphology. 
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1. INTRODUCTION 
 Osteoarthritis is the most common joint disease in the United States (1, 2). Of all 
the chronic degenerative joint diseases, knee osteoarthritis (OA) is the most common in the 
United States, with an estimated lifetime risk of 40% in men and 47% in women (3, 4). 
Ultimately, OA results in disability, economic loss, and lowered quality of life (5).  
 The knee joint is comprised of the distal femur and proximal tibia. Coating the ends 
of these bones is articular cartilage, a thin layer of connective tissue composed of 
chondrocytes and extracellular matrices made up of glycosaminoglycans and collagen that 
function to reduce friction in the movement of the joint. Several ligaments are also located 
within the knee, such as the anterior cruciate ligament (ACL), medial collateral ligament 
(MCL), posterior cruciate ligament, and lateral collateral ligament, all functioning to 
stabilize the joint. The entire knee joint is enveloped by a synovial membrane, which keeps 
synovial fluid within the joint. Synovial fluid, which is rich in hyaluronic acid, functions 
to reduce friction in the movement of the joint by providing cushioning and lubricating 
properties in conjunction with the articular cartilage on the surface of the distal femur and 
proximal tibia (6, 7).  
 The clinical presentation of OA is typically pain and functional disability (8-10). 
Although the exact etiology of OA has not yet been elucidated, it is known that OA is a 
whole-joint disease (10). In OA disease, the articular cartilage can break down due to 
trauma or the release of catabolic enzymes, such as matrix metalloproteinases (MMPs) (11, 
12). Because of the cartilage degeneration, a redistribution of loading occurs in the knee, 
causing the formation of osteophytes as well as bone changes, such as thickening of the 
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subchondral and trabecular bone (10, 11, 13, 14). Additionally, the synovial membrane can 
become inflamed, resulting in the upregulation of pro-inflammatory cytokines, such as IL-
1b and TNFa, which further amplify catabolic processes within the joint (15, 16). The 
concentration of hyaluronic acid in the synovial fluid has also been reported to decrease in 
OA disease (17, 18). 
 There currently exists non-pharmacological and pharmacological treatments of OA 
with varying evidences of efficacy. Non-pharmacological treatments of OA include aerobic 
exercises, heating and icing of the joint, strength training, weight reduction, and knee 
braces (19). Current pharmacological treatments for OA include acetaminophen, 
nonsteroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, oestrogen, and intra-
articular injections of corticosteroids and hyaluronic acid (19, 20). There is no conclusive 
agreement on the administration of some treatments among clinicians and researchers 
because of mixed conclusions on treatment efficacies in clinical settings. For example, 
despite much literature documenting the positive efficacy of intra-articular hyaluronic acid 
injections (17, 18, 21-28), the American Academy of Orthopedic Surgeons (AAOS) 
maintains a strong recommendation against the use of hyaluronic acid for knee OA patients 
because of inconclusive clinical evidence (29). In general, however, current treatments 
target only the symptoms of OA (i.e., pain and joint stiffness) and do not directly modify 
the disease to restore the changes caused by the disease. To date, a disease-modifying drug 
for OA has not been found (19, 20).  
 To study the etiology of knee OA, as well as the efficacy of potential pharmacologic 
therapeutics, animal disease models are required. There have been many animal species 
used to study OA, including mouse, rat, rabbit, and guinea pig (Table 1) (30-32). Selection 
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of an animal model requires the consideration of factors, such as the size of the knee joint, 
thickness of the articular cartilage, postoperative management, joint loading, cost, as well 
as public perception (30). 
Table 1: Summary of animal species and methods of OA induction utilized in knee OA 
studies (30-32). 
 
 
Similarly, there are many different methods of OA induction, including chemical 
injection, impact loading, immobilization, and surgery (Table 1) (30, 32). Spontaneous 
OA can occur in some animals, such as dogs, guinea pigs, and horses; however, this 
progression of OA is slow and may not be consistent among animals within studies (32). 
Selecting the method of OA induction to be used is important and requires the 
consideration of the mechanism of OA progression desired. For example, the use of 
monoiodoacetate (MIA) injection to induce OA differs from surgically-induced models of 
OA because MIA only chemically causes chondrocyte death and is, therefore, only able to 
mimic biochemical changes and not the biomechanical changes that are relevant to the 
disease as well (11, 33). There are also differences in the mechanism and length of OA 
progression among surgically-induced models, such as patellectomy, anterior cruciate 
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ligament transection, medial meniscal tear, partial medial meniscal transection, and medial 
collateral ligament transection (32). When selecting the animal species and method of OA 
induction for a study, these factors need to be considered so that the experimental 
hypothesis can be appropriately addressed. For example, MIA injection to induce OA 
would only be appropriate for studying OA pain, but not the efficacy of regenerative 
therapeutics because MIA would likely cause cartilage degeneration too severe for any 
regenerative potential to remain. 
 For our study, the rat model of OA was selected because of its thicker articular 
cartilage (compared to mice) and lower cost (compared to rabbits) (30). Additionally, a rat 
OA model allows for the pain and behavior tests that are not feasible in rabbits. The method 
of OA induction selected was to surgically induce OA by a combination of ACL transection 
(ACLT) and partial medial meniscal transection (pMMT). Gerwin et al. reported that 
ACLT + pMMT in mature rats causes progressive cartilage degeneration that is slower than 
medial meniscal transection only, but faster and more severe than ACLT only, resulting in 
a more representative progression of OA disease (33). Because a surgical model of OA 
induction was used, the findings reported in this study are more relevant to OA caused by 
physical injury, such as ACL tears or other forms of trauma (post-traumatic OA, PTOA) 
compared to spontaneous or idiopathic OA.  
 Because behavioral, histological, and bone morphological data are commonly 
obtained in OA pharmacological efficacy studies, it is important to characterize these 
measurements in an OA model as to establish baseline measurements for those parameters. 
Bagi et al. previously reported correlations between micro-computed tomography (µCT) 
imaging, histology, and functional capacity in the medial meniscal tear rat model of OA 
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(34). However, preliminary studies performed utilizing minimally invasive surgical 
techniques within our laboratory suggest that a combined ACLT and pMMT model of OA 
results in a milder, but detectable progression of PTOA disease, compared to ACLT and 
MMT surgeries by themselves. Therefore, it is important to characterize the changes in 
histological grading, behavioral analyses, and µCT quantifications in the ACLT + pMMT 
rat model of OA. In addition, a current clinical standard for OA disease management, an 
intra-articular injection of a high molecular weight hyaluronic acid (hylan G-F 20), was 
administered to a group of animals to establish baseline measurements for the changes 
observed resulting from this method of OA treatment (21, 28, 35, 36). We hypothesized 
that 1) the ACLT + pMMT procedure will induce functional and bone changes 
characteristic of PTOA, 2) intra-articular injections of hyaluronic acid will attenuate early 
PTOA changes in cartilage and bone, and 3) one outcome measure can be identified as the 
most sensitive parameter for characterizing PTOA changes among the multiple outcome 
measures obtained in this study.
 6 
2. METHODS 
2.1: Animals 
Institutional Animal Care and Use Committee (IACUC) approval was obtained for 
all in vivo procedures (Protocol: S08294). Male 9-10 weeks-old Wistar rats (Harlan 
Laboratories, Indianapolis, IN, USA) weighing approximately 330 g were used for this 
study. A total of 24 rats were split equally among 3 groups: hyaluronic acid injection (HA), 
PBS injection (PBS) and sham groups. At 0W of the study, there was a significantly higher 
average body weight in the PBS (365.6 g, p<0.0001) and HA (355.1 g, p<0.0001) groups 
when compared to that of the Sham group (267.5 g). However, at 9W of the study, there 
were no significant differences in body weight among the groups (p=0.1508). On average, 
there was a 133 g weight gain among all animals in the study.  
 
 
Figure 1: Summary of the experimental timeline. ACLT and pMMT procedures were 
performed at 0W, and treatment injections (PBS or HA) were administered at 1W. 
Incapacitance testing was performed every week of the study, whereas Von Frey testing 
was performed every 2 weeks after 2W. µCT and histological analyses were performed 
after euthanasia of the animals. 
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2.2: Surgery 
General anesthesia was induced by an intramuscular injection of a mixture of 
ketamine (75 mg/kg, Zetamine®; VETone, Boise ID, USA), xylazine (3 mg/kg, AnaSed®; 
LLOYD Laboratories, Shenandoah, IA, USA), and buprenorphine (0.03 mg/kg, Buprenex®; 
Reckitt Benckiser Pharmaceuticals, Richmond, VA, USA) for sedation and analgesia prior 
to the surgery. Isoflurane inhalation (3%) was used to maintain anesthesia. Surgical 
procedures were performed only on the right knee, leaving the left knee as an unoperated 
contralateral control. The knee was shaved and prepared antiseptically. For the HA and 
PBS groups, a 3 cm paramedian incision was made from the distal patella toward the 
proximal tibial plateau. The joint capsule immediately medial to the patellar tendon was 
incised and opened. Blunt dissection of the fat pad over the intercondylar area was then 
performed to expose the intercondylar region to provide visualization of the anterior 
cruciate ligament (ACL). The patella was dislocated laterally to give a greater exposure of 
the femorotibial joint. The ACL and the anterior half of the medial meniscus were 
transected (ACLT + pMMT). The patella was then replaced, and the fascia and 
subcutaneous layer were sutured using 4-0 absorbable sutures and surgical glue was 
applied to the incision site. The Sham group received the same surgical exposure without 
transection of the ACL and medial meniscus. 
2.3: Knee Injections 
One week following surgery, animals in the HA group received a 50 µL intra-
articular injection of high molecular weight hyaluronic acid (hylan G-F 20, Synvisc®; 
Genzyme Corporation, Cambridge, MA, USA) in the right knee joint. Animals in the PBS 
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group received a 50 µL intra-articular injection of phosphate-buffered saline. Contralateral 
knees were not injected. Sham group animals were also not injected. 
2.4: Von Frey Nociception Test 
The Von Frey nociception test has been reported as a method for measuring 
mechanical nociception in rodents (37, 38). Specifically, the Von Frey test has been 
reported as a method for quantifying pain due to OA (39, 40). The Von Frey test was 
performed on the rats at 1 week after the surgery and at every 2 weeks from that point 
onwards. Rats were placed on a suspended wire mesh which allowed for full access to the 
hind paws. Rats were first placed on the wire mesh for 20 minutes before testing at each 
time point to allow for rats to acclimate to the environment. Von Frey filaments of different 
stiffness (4.31, 4.56, 4.74, 4.93, and 5.18 g) were incrementally applied perpendicular to 
the center of the plantar surface of each hind paw for 6-8 seconds. A positive response was 
recorded when a rapid paw withdrawal was observed in response to the filament 
presentation. Using the up-down method, 50% paw withdrawal threshold was determined 
as described by Chaplan et al. (41, 42). 
 
Figure 2: Von Frey nociception test was performed on rats to assess mechanical 
nociception after ACLT + pMMT surgery. 
 
 
 
 
9 
2.5: Incapacitance Test 
Incapacitance testing has been reported as an assessment of inflammation or pain 
in the hind limbs by measuring static weight bearing (43, 44). For every week of the study, 
static weight bearing of the hind limbs was tested using an Incapacitance Tester (Columbus 
Instruments, Columbus, OH, USA). Two sensors on the machine independently measure 
the weight loaded on the left and right hind limbs. To limit the variation in measurements 
due to the position and posture of the rat within the incapacitance chamber, measurements 
are taken only when (i) the rat is stationary, (ii) the left and right hind paws are aligned at 
the same position on each sensor, and (iii) the left and right front paws are placed at the 
same position on the chamber wall so that one paw is not above the other. The force applied 
by each hind limb was averaged over a 5 second period. For each animal at each time point, 
10 measurements were obtained. Hind limb weight distribution (HLWD) was expressed 
relative to the right hind limb as a percentage of the total weight applied by both hind limbs 
by dividing the weight exerted by the right hind limb by the sum of the weights of both 
right and left hind limbs (Right / Right + Left). The percentages of all 10 measurements at 
each time point were then averaged for each animal. 
 
Figure 3: Static weight bearing was tested by using an incapacitance tester to assess 
inflammation or pain in the hind limbs following ACLT + pMMT surgery. 
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2.6: Sample Collection 
At 9 weeks after surgery, animals were euthanized. For both left and right sides, 
the entire knee joint was harvested and stored in 10% formalin for histological and µCT 
bone analyses. 
2.7: Micro-Computed Tomography (µCT) Scanning and Analyses 
µCT scanning was performed for three-dimensional (3D) bone morphological 
analyses. Left and right knee joints were µCT scanned with a Skyscan 1076 µCT scanner 
(Bruker, Kontich, Belgium) at a 9 µm resolution, 70 kV, 142 µA, using a 1.0 mm aluminum 
filter with an average scan time of 1 hour per knee joint. Knees were wrapped in formalin-
soaked gauze and placed in 50 mL conical tubes for scanning. The scanning region was 
selected such that the distal femoral epiphysis and metaphysis and the proximal tibial 
epiphysis and metaphysis were included in the scan for bone morphological analyses. 
Hydroxyapatite phantom rods (4 mm diameter; 0.25 and 0.75 g/cm3) were scanned with 
the samples for bone mineral density (BMD) calibration and analyses.  
Reconstructed transaxial bitmap image files for each scan were first opened using 
Dataviewer software (Bruker, Kontich, Belgium) to rotate the scans to align the femur, 
tibia, and joint space with the transaxial, coronal, and sagittal planes. Then, the rotated 
datasets were opened in CT-Analyser (Bruker, Kontich, Belgium) to select the regions of 
interest (ROI) for analysis. Four ROIs were manually selected for each knee for individual 
analysis of the femur epiphysis, femur metaphysis, tibia epiphysis, and tibia metaphysis 
(Figure 4). ROIs were carefully drawn to include only the trabecular bone and to exclude 
the cortical bone. For the femur, the epiphysis was defined as any trabecular bone distal to 
the epiphyseal plate and the metaphysis was defined as any trabecular bone within 4 mm 
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proximal from the epiphyseal plate. For the tibia, the epiphysis was defined as any 
trabecular bone proximal to the epiphyseal plate and the metaphysis was defined as any 
trabecular bone within 4 mm distal from the epiphyseal plate. Using CT-Analyser, all 4 
ROIs for each knee sample were analyzed for the following parameters: bone mineral 
density (BMD), trabecular thickness (Tb.Th), trabecular number (Tb.N), trabecular 
separation (Tb.Sp), percent bone volume (BV/TV), and bone surface density (BS/TV) (45). 
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Figure 4: A) Four bone segments (femur metaphysis, femur epiphysis, tibia epiphysis, 
tibia metaphysis) were manually selected for bone morphological analyses. The epiphyseal 
plates are indicated by the arrows. B) A transaxial µCT slice of a tibia metaphysis before 
and C) after ROI selection (shown in red). ROI were manually selected as to include only 
trabecular bone and to avoid cortical bone. 
 
2.8: Histology 
 After µCT scanning, knee samples were prepared for histological analyses. Knee 
samples were decalcified using a solution containing 7% formalin and 10% formic acid 
(Cal-Ex II; Fischer Scientific, Hampton, NH). After decalcification, knee samples were 
embedded in paraffin, and coronal sections were made to visualize the medial tibial plateau 
(MTP) of the tibial articular cartilage. The slices then were stained with safranin-O to detect 
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the glycosaminoglycan content of the MTP cartilage. Slides were scanned at 40X objective 
using a Leica SCN400 Slide Scanner (Leica, Wetzlar, Germany). 
 Histological scoring of the MTP for OA degeneration was performed using the 
Osteoarthritis Research Society International (OARSI) scoring system as reported by 
Pritzker et al. (46). The OARSI score is dependent on two histopathological assessments: 
grade and stage. The histopathology grade assessment is dependent on the morphological 
features of the articular cartilage due to OA, such as surface irregularities, cell death, 
cartilage matrix loss, and decreased Safranin O staining with grades ranging from 0 to 6 
(Table 2). The histopathology stage assessment ranges from stage 0 to 4, depending on the 
percentage of the total surface or area affected by the OA changes (Table 3). If no changes 
in structure or morphology are observed, then a stage of 0 is assigned. If more than 50% of 
the total surface or area is affected by OA changes, then a stage of 4 is assigned. The final 
OARSI score is obtained by multiplying the grade and stage assessments, resulting in 
scores ranging from 0-24, with 24 representing the most severe OA cartilage degeneration. 
Histological scoring was performed by two independent observers and the inter-observer 
agreement was calculated.  
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Table 2: OARSI score histopathological grade assessment as reported by Pritzker et al.(46). 
 
 
 
Table 3: OARSI score histopathological stage assessment as reported by Pritzker et al.(46). 
 
 
2.9: Statistics 
All statistical analyses were performed using GraphPad Prism 7.0 (GraphPad, La 
Jolla, CA, USA). Two-way ANOVA tests were performed to test for significant effects of 
time and treatment. One-way ANOVA tests were performed to test for significant effects 
 
 
 
15 
of treatment. Fisher’s PLSD post hoc tests were performed to find significant differences 
due to multiple comparisons. A Mann-Whitney U test was performed to test for significant 
differences between PBS and HA histology scores. All values are displayed as mean ± 
standard error.  
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3. RESULTS 
3.1: Von Frey Nociception  
All animals were tested for nociceptive pain using Von Frey filaments at 1 week 
after surgery, at 1 week after injection treatments, and at every 2 weeks afterward until the 
end of the 9-week study. At 0W, all animals had a 50% paw withdrawal threshold of 15 g. 
The only significant differences among all groups at all time points was observed at 1W, 
where a significant decrease in 50% paw withdrawal threshold was observed in the PBS 
(p<0.01) and HA (p<0.01) groups when compared to that of the Sham group (Figure 5). 
By 8W, all groups had returned to a 15 g 50% paw withdrawal threshold. 
 
 
Figure 5: Von Frey nociception test. 50% paw withdrawal threshold was determined using 
the up-down method (41). Significant differences were observed between Sham and HA 
(p<0.05) and PBS and HA (p<0.01) only at 1 week after the surgery, before the intra-
articular injection treatments. No significant differences among groups were observed at 
any other time points. There was a significant effect of time (p<0.0001), but not treatment 
(p=0.2263). 
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3.2: Incapacitance 
Incapacitance testing to assess changes in static weight bearing was performed prior 
to the surgery and weekly postoperatively. Hind limb weight distribution (HLWD) was 
expressed relative to the right hind limb as a percentage of the total weight applied by both 
hind limbs. A two-way ANOVA found both time and treatment to have significant effects 
on HLWD (p<0.0001). Before the surgery, HLWD was 50.1% in all animals in all groups 
(Figure 6). At one week after the surgery before treatment injections were administered, 
HLWD in the HA (40.5%) and PBS (38.4%) groups were significantly lower than that of 
the Sham group (48.9%, p<0.01). After the treatment injections were administered, HLWD 
of the HA and PBS groups were still significantly lower than that of the Sham group 
(p<0.01); however, no significant differences were observed among groups from 4 weeks 
post-surgery to the end of the study.  
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Figure 6: Hind limb weight distribution (HLWD) for all 3 treatment groups at every time 
point is shown. HLWD is expressed relative to the right hind limb as a percentage of the 
total weight applied by both hind limbs by dividing the weight exerted by the right hind 
limb by the sum of the weights of both right and left hind limbs. The HA (p<0.01) and PBS 
(p<0.01) groups had significantly lower HLWD compared to the Sham group at 1W, 2W, 
and 3W time points. No other significant differences among groups were observed at any 
other time points. 
 
3.3: Histological Analyses 
 Coronal sections of the MTP were stained with safranin-O and scored using the 
OARSI score as described by Pritzker et al. (46). Histological scoring was performed only 
for the PBS and HA groups, as the histological processing of the Sham group samples is 
ongoing. Because the majority of the cartilage defects were not severe, much attention was 
given to observe small changes, such as cell death or cell clustering, in the MTP that would 
indicate OA changes. Samples receiving an OARSI score of 0 generally had normal 
articular cartilage, with smooth cartilage surface, clear layered organization of matrix and 
chondrocytes, and retention of Safranin-O staining (Figure 7A). Samples receiving higher 
OARSI scores were observed to have cell death, superficial fibrillation of the matrix, 
depletion of Safranin-O staining, and vertical fissures. The inter-class reliability coefficient 
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from the scores of two independent observers was 0.943. There were no statistical 
differences found between mean scores of the PBS and HA groups (p=0.6298, Figure 7B). 
However, OARSI scores in the PBS group tended to have a higher variation than that of 
the HA group. In the PBS group, the highest OARSI score received by one sample was 9.0, 
whereas the highest score received in the HA group was 5.0.  
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Figure 7: A) Histology of the coronal sections of the medial tibial plateau (MTP) from the 
PBS and HA groups. Sections were stained with safranin-O. The left MTP samples show 
normal articular cartilage, with smooth cartilage surface, layered organization of matrix 
and chondrocytes, and retention of Safranin-O staining (red). The right MTP samples show 
cell death, superficial fibrillation of the matrix, depletion of Safranin-O staining, and a 
fissure (PBS, Right, indicated by the arrow). The OARSI score assigned for each sample 
shown is indicated. B) Average OARSI scores of PBS and HA groups. Dots indicate scores 
of individual samples. Although MTP samples from the PBS group tended to have higher 
OARSI scores when compared to those of the HA group, a Mann-Whitney U test found no 
significant differences between the two groups (p=0.6298). 
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3.4: µCT Analyses 
Data for the µCT analyses are represented as absolute values as well as normalized 
values (Right/Left). Data are represented as normalized values because the differences 
between right and left knees within the same animal were larger than differences among 
treatment groups in some parameters. There were no significant differences in 
measurements among left, contralateral knees of different treatment groups for trabecular 
thickness (p=0.1331), trabecular separation (p=0.3136), percent bone volume (p=0.8302), 
and bone surface density (p=0.1262), although significant differences were observed for 
bone mineral density (p=0.0002) and trabecular number (p<0.0001). Three animals from 
the PBS group were excluded from µCT analyses because of abnormal ring artifacts in the 
scan images.  
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Figure 8: Representative coronal and transaxial cross-sections of tibias from the Sham and 
PBS groups 9 weeks after ACLT + pMMT. Upon visual inspection, there are no remarkable 
differences between the left and right tibias in the Sham group. However, the right tibia 
appears to have decreased bone mass compared to the left tibia in the PBS group. Bone 
mineral density (BMD) and trabecular thickness (Tb.Th) values the samples are shown. 
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3.4.1: Bone Mineral Density 
 In general, absolute bone mineral density (BMD) in the Sham group was higher 
than both PBS and HA groups in all bone segments analyzed. Significant effects of 
treatment on BMD were found in the femur epiphysis, femur metaphysis, and tibia 
epiphysis (p<0.001 for all) but not in the tibia metaphysis (p=0.1387). In the femur 
epiphysis, femur metaphysis, and tibia epiphysis, BMD of the Sham group was 
significantly higher than that of the PBS and HA groups (p<0.01 for all, Figure 9). In the 
femur metaphysis, BMD of the Sham, PBS, and HA groups was found to be 1.1070, 0.5766, 
and 0.6999 g/cm3, respectively. In the tibia epiphysis, BMD of the Sham, PBS, and HA 
groups was found to be 1.4660, 0.8184, and 0.9489 g/cm3, respectively. The HA group also 
tended to have a higher BMD compared to the PBS group at all bone segments, although 
no significant differences were found.   
 When BMD was normalized to the contralateral controls, significant differences 
were only found between Sham/PBS and HA/PBS in the femur metaphysis and between 
Sham/PBS in the tibia epiphysis (p<0.05 for all), although no significant effect of treatment 
was found (Figure 9). No significant differences were found between Sham and HA groups 
at any bone segment analyzed. 
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Figure 9: Bone mineral density (BMD) of the femur epiphysis (A, B), femur metaphysis 
(C, D), tibia epiphysis (E, F) and tibia metaphysis (G, H) among Sham, PBS, and HA 
treatment groups at 9 weeks post-ACLT + pMMT surgery. Absolute (A, C, E, G) and 
normalized (B, D, F, H) data are shown. * = p<0.05, ** = p<0.01. 
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3.4.2: Trabecular Thickness 
 A significant effect of treatment on absolute trabecular thickness (Tb.Th) was found 
for all analyzed bone segments (p<0.05 for all). Absolute Tb.Th was significantly higher 
in the HA group compared to the PBS group at all analyzed bone segments (Figure 10). In 
the femur metaphysis, Tb.Th in the Sham group (0.1150 mm) was significantly higher than 
that of the PBS group (0.1028 mm, p<0.05). Absolute Tb.Th in the of the HA group in the 
femur epiphysis and tibia metaphysis was also found to be significantly higher than that of 
the Sham group. 
 When Tb.Th was normalized to contralateral controls, a significant effect of 
treatment was only found in the femur metaphysis and tibia epiphysis. Similarly, the only 
significant differences found among treatment groups were in the femur metaphysis and 
tibia epiphysis (Figure 10). In the femur metaphysis, both Sham (0.9934) and HA (1.006) 
groups were significantly higher in normalized Tb.Th when compared to that of the PBS 
group (0.8976, p<0.05). In the tibia epiphysis, the Sham group (1.008) was found to have 
a significantly higher normalized Tb.Th compared to the PBS group (0.8811, p<0.01). 
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Figure 10: Trabecular thickness (Tb.Th) of the femur epiphysis (A, B), femur metaphysis 
(C, D), tibia epiphysis (E, F) and tibia metaphysis (G, H) among Sham, PBS, and HA 
treatment groups at 9 weeks post-ACLT + pMMT surgery. Absolute (A, C, E, G) and 
normalized (B, D, F, H) data are shown. * = p<0.05, ** = p<0.01. 
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3.4.3: Trabecular Number 
 A significant effect of treatment on absolute trabecular number (Tb.N) was found 
at all analyzed bone segments (Figure 11). Absolute Tb.N in the HA group was found to 
be significantly lower than that of the Sham group at all analyzed bone segments (p<0.05 
for femur epiphysis and tibia metaphysis, p<0.01 for femur metaphysis and tibia epiphysis). 
Absolute Tb.N in the PBS group was also significantly lower than that of the Sham group 
in the femur metaphysis, tibia epiphysis, and tibia metaphysis (p<0.01 for all). However, 
when Tb.N was normalized to contralateral controls, no significant effects of treatment 
were found at all analyzed bone segments, although a significant decrease in PBS 
normalized Tb.N was found compared to that of the Sham group in the femur metaphysis 
and tibia metaphysis (p<0.05, Figure 11).  
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Figure 11: Trabecular number (Tb.N) of the femur epiphysis (A, B), femur metaphysis (C, 
D), tibia epiphysis (E, F) and tibia metaphysis (G, H) among Sham, PBS, and HA 
treatment groups at 9 weeks post-ACLT + pMMT surgery. Absolute (A, C, E, G) and 
normalized (B, D, F, H) data are shown. * = p<0.05, ** = p<0.01. 
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3.4.4: Trabecular Separation 
 No significant effects of treatment on absolute trabecular separation (Tb.Sp) were 
found at all analyzed bone segments (Figure 12). However, a significant increase in 
absolute Tb.Sp was found in the HA group (0.2856 mm) when compared to that of the 
Sham group (0.2083 mm) in the femur metaphysis (p<0.05). A significant increase in 
absolute Tb.Sp was also found in the PBS group (0.212 mm) when compared to that of the 
Sham group (0.1768 mm) in the tibia epiphysis. When Tb.Sp was normalized to 
contralateral controls, significant effects of treatment and significant differences among 
treatment groups were not found at any analyzed bone segments (Figure 12). 
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Figure 12: Trabecular separation (Tb.Sp) of the femur epiphysis (A, B), femur metaphysis 
(C, D), tibia epiphysis (E, F) and tibia metaphysis (G, H) among Sham, PBS, and HA 
treatment groups at 9 weeks post-ACLT + pMMT surgery. Absolute (A, C, E, G) and 
normalized (B, D, F, H) data are shown. * = p<0.05, ** = p<0.01. 
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3.4.5: Percent Bone Volume 
 Significant effects of treatment on absolute percent bone volume (BV/TV) were 
found in the femur metaphysis and tibia epiphysis (p<0.05 for both, Figure 13). Absolute 
BV/TV in the PBS group was also found to be significantly lower than that of the Sham 
group in the femur metaphysis, tibia epiphysis, and tibia metaphysis (p<0.01 for femur 
metaphysis and tibia epiphysis, p<0.05 for tibia metaphysis).  
 When BV/TV was normalized to contralateral controls, significant effects of 
treatment on BV/TV were maintained in the femur metaphysis (p=0.0431), but not the tibia 
epiphysis (p=0.0591). Nevertheless, a significant decrease in normalized BV/TV was 
found in the PBS group compared to that of the Sham group in both the femur metaphysis 
and tibia epiphysis (p<0.05 for both, Figure 13). A significant increase in normalized 
BV/TV was also found in the HA group (1.011) compared to that of the PBS group (0.8158) 
in the femur metaphysis (p<0.05).  
 
 
 
32 
 
Figure 13: Percent bone volume (BV/TV) of the femur epiphysis (A, B), femur metaphysis 
(C, D), tibia epiphysis (E, F) and tibia metaphysis (G, H) among Sham, PBS, and HA 
treatment groups at 9 weeks post-ACLT + pMMT surgery. Absolute (A, C, E, G) and 
normalized (B, D, F, H) data are shown. * = p<0.05, ** = p<0.01. 
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3.4.6: Bone Surface Density 
 A significant effect of treatment on absolute bone surface density (BS/TV) was 
found only at the tibia metaphysis (p=0.0428). A significant decrease in BS/TV in the tibia 
metaphysis was found in the PBS group (10.23 mm-1) when compared to that of the Sham 
group (12.68 mm-1). However, when BS/TV was normalized to contralateral controls, 
significant effects of treatment and significant differences among treatment groups were 
not found at any analyzed bone segments (Figure 14). 
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Figure 14: Bone surface density (BS/TV) of the femur epiphysis (A, B), femur metaphysis 
(C, D), tibia epiphysis (E, F) and tibia metaphysis (G, H) among Sham, PBS, and HA 
treatment groups at 9 weeks post-ACLT + pMMT surgery. Absolute (A, C, E, G) and 
normalized (B, D, F, H) data are shown. * = p<0.05, ** = p<0.01. 
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4. DISCUSSION 
 In this study, ACLT + pMMT surgeries were performed on rats to investigate 
behavioral, cartilage, and bone changes in early PTOA. Additionally, an intra-articular 
injection of hyaluronic acid was administered at 1 week post-surgery to investigate its 
attenuating effect on early PTOA changes in cartilage and bone. The results indicate that 
ACLT + pMMT surgery resulted in a temporary contralateral preference in static weight 
bearing, minor degeneration of the articular cartilage, and generally decreased bone quality. 
However, among the parameters analyzed, trabecular thickness of the µCT analyses was 
the most sensitive parameter for characterizing PTOA changes in the ACLT + pMMT 
model among all measured parameters. Treatment with HA was also found to attenuate the 
progression of PTOA changes in articular cartilage and bone morphology. 
 The animals used in this study were 9-10 weeks old at the time of the surgeries, 
which is beyond the 8-week threshold for rat adulthood (47). Although all animals were 
skeletally mature at 0W, differences in body weight among treatment groups were observed. 
Since animals of the same strain were expected from the vendor, similar weights among 
the animals were expected as well. However, these differences could be due to the 1-week 
difference in age among some animals in the study. While most animals may have already 
reached the plateau of the growth curve, it is possible that rats that were 1 week younger 
were still at the late stages of exponential growth (48). At the end of the study, no 
significant differences in body weight were observed among groups. Furthermore, the age 
of the rats used in this study resembles that of young adult humans (47). It would be 
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important, however, to investigate the effects of age on responses to ACLT + pMMT in a 
future study. 
The ACLT + pMMT combination surgery for knee OA induction was utilized in 
this study because preliminary studies performed in our lab found that ACLT + pMMT 
showed a milder, but detectable degeneration progression of OA cartilage and bone 
changes compared to ACLT or MMT alone. Furthermore, it was expected to observe 
degeneration of the articular cartilage and bone by performing minimally invasive ACLT 
+ pMMT surgeries to reproduce PTOA in a rat model similar to that in humans due to ACL 
tear and meniscus damage.  
 The changes observed in this study reflect early PTOA changes because the 
terminal time point in this study was 9 weeks after the ACLT + pMMT surgery. PTOA is 
a disease that develops over a long period of time, taking anywhere from 6 months to 
decades to develop (49-51). For example, it has been reported that it took, on average, 22 
years after sustaining a knee injury for symptomatic OA be diagnosed in a young cohort of 
medical students who had experienced knee injuries (mean age at time of injury: 22 years) 
(52). Therefore, the scope of this study is limited to early PTOA changes and not moderate- 
or end-stage PTOA.  
 The changes in behavior due to ACLT + pMMT were tested using Von Frey 
nociception and incapacitance tests. In the Von Frey nociception test, significant 
differences were only observed at 1 week after the surgeries. At 0W, all animals showed 
negative responses when hind paws were stimulated with Von Frey filaments, with 50% 
paw withdrawal threshold at 15 g for all groups (Figure 5). At 1W the 50% paw withdrawal 
threshold of the Sham group decreased along with that of the PBS and Sham groups. At 
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1W, the HA group was found to be significantly lower than that of the Sham and PBS 
groups. The 1W Von Frey measurements were taken before the treatment injections were 
administered at 1W; therefore, the observed differences are not due to any injection 
treatment and must be due to the surgery. Furthermore, no significant differences were 
observed at any other time points, and all groups had generally returned to normal by 4W. 
This suggests that the decreases in 50% paw withdrawal threshold at 1W are mainly due to 
pain from the skin incision, joint capsule incision, and patellar dislocation during the 
surgical procedures and not the ACLT + pMMT procedures. 
 In contrast, the incapacitance tests showed that HLWD of the Sham group was 
significantly higher than both HA and PBS groups at 1W, 2W, and 3W time points. Unlike 
what was observed in the Von Frey nociception test, HLWD of the Sham group remained 
around 50% throughout the duration of the study. In contrast, both HA and PBS groups 
dropped to approximately 40% HLWD at 1W. This suggests that the observed changes in 
static weight bearing are due to ACLT + pMMT and not to any surgical access procedures 
performed. At 4W, 3 weeks after the injection treatments, both HA and PBS groups had 
returned to normal HLWD. The fact that there were no significant differences in HLWD 
between PBS and HA groups at any time point suggests that a mere 4 weeks of recovery 
after ACLT + pMMT surgery is sufficient to regain normal HLWD. Therefore, the 
injection treatments had little to no effect on restoring static weight bearing due to ACLT 
+ pMMT surgery. 
 Although histological analyses of the PBS group tended to yield higher OARSI 
scores compared to that of the HA group, there were no significant differences between the 
two groups (Figure 7B). Most histological changes observed in the MTP due to ACLT + 
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pMMT surgery in this study were minor. However, there have been publications reporting 
much more severe histological changes due to surgical induction of knee OA, some even 
at time points earlier than reported in our study (33, 34, 53-55). For example, Gerwin et al. 
reported cartilage lesions spanning the entire depth of the knee cartilage at 3 weeks 
following full MMT surgery, which translates to an OARSI score of 10 to 12 (33). However, 
in the present study and in our pilot studies, such severe cartilage lesions were not observed 
after ACLT only, MMT only, or ACLT + pMMT surgical procedures. The highest OARSI 
score observed from a single sample in this 9-week study was a 9 from the PBS group, 
although the average score of the group was 3.6 (Figure 7B). It is possible that the 
discrepancy in cartilage degeneration is due to inconsistencies in surgical invasiveness 
among labs. During the surgical procedures performed in this study, incisions were made 
as minimally invasive as possible as to avoid bleeding and prevent blood from entering the 
joint. This is important because damage to articular cartilage due to the mere presentation 
of blood in joints (hemarthrosis) has been reported (56-61). In this study, minimally 
invasive surgical techniques were utilized to investigate OA changes without the 
confounding factor of hemarthrosis such that changes due only to the ACLT + pMMT 
surgery itself could be observed. Because there were no significant differences in 
histological changes found between the injection treatment groups in this 9-week study, 
histological analyses are not ideal for identifying early PTOA changes in the knee.  
 In the µCT analyses, bone quality was generally higher in the Sham and HA groups 
compared to the PBS group, and no significant differences were found between the Sham 
and HA groups (Table 4). Most of the significant differences found between treatment 
groups were present in the femur metaphysis and the tibia epiphysis. Although significant 
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differences in absolute values between groups were observed at all analyzed bone segments 
for some bone parameters, these significant differences remained only in the femur 
metaphysis and tibia epiphysis when the data were normalized to the left contralateral 
control knees (Figure 10). This suggests that the femur metaphysis and tibia epiphysis are 
particularly sensitive to early PTOA changes in bone due to ACLT + pMMT surgery. 
Table 4: Summary of µCT results. Differences observed normalized values of the femur 
metaphysis are shown. Directions within each column are relative to the first group 
mentioned. ­ = Significant increase, « = No significant differences. 
 
 Furthermore, among the bone parameters measured, only BMD, Tb.Th, and BV/TV 
maintained significant effects of treatment on the measured parameter after the data was 
normalized to those of contralateral controls. These results are remarkable because a 
previous 10-week study using MMT in rats reported no significant changes in BMD and 
Tb.Th but significant decreases in BV/TV and Tb.N, and significant increases in Tb.Sp 
(34). These inconsistences in findings support the idea that surgical invasiveness needs to 
be standardized among labs so that bone changes due to surgical induction of OA are 
consistent. Nevertheless, the bone segment that consistently maintains significant effects 
of treatment after normalization of both BMD and BV/TV is the femur metaphysis. 
However, in Tb.Th, significant effects of treatment after normalization is maintained in 
both the femur metaphysis and tibia epiphysis (Figure 10). Therefore, based on these 
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results, it can be concluded that the femur metaphysis is the bone segment most sensitive 
to ACLT + pMMT surgery, and that among the bone parameters analyzed in this study, 
Tb.Th is the most sensitive parameter in detecting PTOA changes. 
 When comparing bone parameter measurements between the injection treatment 
groups, the HA group was found to have a higher BMD, Tb.Th, and BV/TV compared to 
those of the PBS group (Table 4). Additionally, the Sham group showed significantly 
higher normalized BMD, Tb.Th, Tb.N, and BV/TV compared to the PBS group, and there 
were no significant differences between Sham and HA groups for any of the analyzed bone 
parameters. ACLT+ pMMT surgery was expected to cause a decrease in bone quality, as 
evidenced by the PBS group. However, some of the bone parameters measured in the HA 
injection group were closer to those of the Sham group. This suggests that injection of HA 
at one week after ACLT + pMMT surgery was successful in attenuating some early PTOA 
changes in bone quality. These results add to the many reports on the efficacy of HA 
injection in animal models (17, 18, 21-28), although the use of HA for clinical treatment 
of knee osteoarthritis is still not recommended (29). In the future, it may be useful to 
investigate the effects of administrating HA injections at different time points on PTOA 
changes. 
 The bone changes observed in this study can be attributed to disuse of the operated 
hind limb. The incapacitance tests revealed significant differences in static weight bearing 
in the PBS and HA groups at 1W, 2W, and 3W time points when compared to the Sham 
group, which maintained roughly 50% HLWD throughout the duration of the study (Figure 
6). From 4W onward, all groups maintained approximately 50% HLWD until the end of 
the study. The recovery of HLWD after 4W suggests that ACL injury itself and not 
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cartilage degeneration was the cause of the significant differences observed at earlier time 
points, because true cartilage degeneration would have resulted in a progression of lower 
HLWD. These results show that after ACLT + pMMT surgery there was a preference for 
bearing weight on the left, contralateral knee. This means that less weight was applied to 
the right hind limb than it was normally accustomed to experiencing at the 0W time point 
before the surgical procedures. According to Wolff’s law, a bone will undergo 
morphological changes to adapt to loads that are applied to it (62, 63). Similarly, a bone 
will undergo morphological changes to adapt to loads removed from it. This may explain 
why BMD, Tb.Th, Tb.N, and BV/TV were decreased in the femur and tibia in the PBS 
group at the end of the study. This also suggests that 3 weeks of uneven static hind limb 
weight bearing after ACLT + pMMT could affect bone measurements 6 weeks later, 
although more bone analyses at different time points are required to support this conclusion.  
  It is important to note that Wistar rats were used in this study. Although many knee 
OA studies report using Sprague-Dawley rats, Lewis rats are preferred for MMT and 
ACLT + pMMT models because Lewis rats tend to exhibit uniform cartilage degeneration 
across the MTP, whereas Sprague-Dawley rats tend to exhibit greater cartilage 
degeneration in the center of the MTP (33). However, Wistar rats were selected for this 
study based on other reports using Wistar rats to study pain and related changes in behavior 
due to induced knee OA (43, 54, 64, 65). Although significant changes in the MTP due to 
ACLT + pMMT were not found in this study using Wistar rats, significant changes in static 
weight bearing and bone morphology were still found. Given that this 9-week study 
resulted in early PTOA changes, it is possible that significant changes in the knee articular 
cartilage could develop if PTOA was allowed a longer time to progress. 
 
 
 
42 
 In this study, ACLT + pMMT surgery resulted in minor changes in the articular 
cartilage. Because clinical OA is typically marked with the wearing a way of articular 
cartilage, exposing the subchondral bone (3, 10), it may be useful to introduce a transection 
of the medial collateral ligament (MCL) in addition to ACLT + pMMT to cause more 
severe cartilage damage (66, 67). However, caution must be taken to not cause severe 
cartilage damage to the point of no regeneration potential, especially for investigating 
therapeutic interventions for knee OA. Reproducing end-stage OA in animal models holds 
little value for potential therapeutic interventions because clinical end-stage OA typically 
results in total knee arthroplasty. Therefore, an ideal animal model used for investigating 
therapeutic interventions for knee OA in the future should develop, at most, moderate knee 
OA cartilage degeneration to preserve the regenerative potential of the knee cartilage and 
consistently use minimally invasive surgical techniques to avoid unwanted joint damage 
during surgery (33).  
 Additionally, intra-articular HA injections administered at 1 week after ACLT + 
pMMT surgeries were found to attenuate cartilage and bone changes. Histological scores 
of the HA group tended to be lower than that of the PBS group, suggesting that cartilage 
degeneration was attenuated. Bone µCT measures in the HA group were closer to that of 
the Sham group and were significantly greater than that of the PBS group, suggesting that 
HA injections also attenuate OA bone changes. It is important to note that HA injections 
are administered to prevent PTOA disease progression and do not aim to restore cartilage 
and bone changes that may have already occurred because of the disease. In this study, 
PTOA was allowed to progress for 8 weeks after ACLT + pMMT surgery, allowing for 
early-PTOA changes to occur in the cartilage and bone. Therefore, it would be important 
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to investigate the effects of HA injection given a longer time course for PTOA to progress 
in a future study.  
 In conclusion, this study found that bone analyses, specifically trabecular thickness 
measurement, can be used as outcome measures of knee OA treatment. Additionally, 
surgical induction of knee OA by ACLT + pMMT in Wistar rats caused early PTOA 
changes, although intra-articular HA injections were successful in attenuating these 
changes, as suggested by static weight bearing tests and confirmed by µCT bone analyses.  
I would like to acknowledge Kenji Kato, Shingo Miyazaki, and Junichi Yamada of 
the Skeletal Translational Research Laboratory in the Department of Orthopaedic Surgery 
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